Aquaporin 2 Mutations in Trypanosoma brucei gambiense Field Isolates Correlate with Decreased Susceptibility to Pentamidine and Melarsoprol

PLoS Neglected Tropical Diseases

Volumn 7, Issue 10, 2013, Pages

  Graf, Fabrice E ^a,b   Ludin, Philipp ^a,b   Wenzler, Tanja ^a,b   Kaiser, Marcel ^a,b   Brun, Reto ^a,b   Pyana, Patient Pati ^c,d   Büscher, Philippe ^d   de Koning, Harry P ^e   Horn, David ^f   Mäser, Pascal ^a,b  

^a SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

^c Institut National de Recherche Biomedicale   (Congo)

^d INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^e UNIVERSITY OF GLASGOW   (United Kingdom)

^f UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AQUAPORIN 2; GENOMIC DNA; MELARSOPROL; PENTAMIDINE;

AFRICAN TRYPANOSOMIASIS; ARTICLE; BACTERIUM CULTURE; BACTERIUM ISOLATE; CHROMOSOME 10; DRUG SENSITIVITY; GENE AMPLIFICATION; GENE MUTATION; GENOTYPE PHENOTYPE CORRELATION; IC 50; IN VITRO STUDY; NONHUMAN; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; TRYPANOSOMA;

AQUAPORIN 2; DNA, PROTOZOAN; DRUG RESISTANCE; HUMANS; MELARSOPROL; MOLECULAR SEQUENCE DATA; MUTATION; PENTAMIDINE; PROTOZOAN PROTEINS; SEQUENCE ANALYSIS, DNA; TRYPANOCIDAL AGENTS; TRYPANOSOMA BRUCEI GAMBIENSE; TRYPANOSOMIASIS, AFRICAN;

EID: 84887310584     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0002475     Document Type: Article

References (55)

1. Brun R, Blum J, Chappuis F, Burri C, (2010) Human African trypanosomiasis. Lancet 375: 148-159 doi:10.1016/S0140-6736(09)60829-1.
2. Kennedy PGE, (2008) The continuing problem of human African trypanosomiasis (sleeping sickness). Ann Neurol 64: 116-126 doi:10.1002/ana.21429.
3. Torreele E, Bourdin Trunz B, Tweats D, Kaiser M, Brun R, et al. (2010) Fexinidazole-a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness. PLoS Negl Trop Dis 4: e923 doi:10.1371/journal.pntd.0000923.
4. Kaiser M, Bray MA, Cal M, Bourdin Trunz B, Torreele E, et al. (2011) Antitrypanosomal activity of fexinidazole, a new oral nitroimidazole drug candidate for treatment of sleeping sickness. Antimicrob Agents Chemother 55: 5602-5608 doi:10.1128/AAC.00246-11.
5. Nare B, Wring S, Bacchi C, Beaudet B, Bowling T, et al. (2010) Discovery of novel orally bioavailable oxaborole 6-carboxamides that demonstrate cure in a murine model of late-stage central nervous system african trypanosomiasis. Antimicrob Agents Chemother 54: 4379-4388 doi:10.1128/AAC.00498-10.
6. Jacobs RT, Nare B, Wring SA, Orr MD, Chen D, et al. (2011) SCYX-7158, an orally-active benzoxaborole for the treatment of stage 2 human African trypanosomiasis. PLoS Negl Trop Dis 5: e1151 doi:10.1371/journal.pntd.0001151.
7. Mäser P, Wittlin S, Rottmann M, Wenzler T, Kaiser M, et al. (2012) Antiparasitic agents: new drugs on the horizon. Curr Opin Pharmacol 12: 562-566 doi:10.1016/j.coph.2012.05.001.
8. Ehrlich P, (1907) Chemotherapeutische trypanosomen-studien. Berl Klin Wochenzeitschrift 44.
9. Hawking F, (1937) Studies on Chemotherapeutic Action I. the Absorption of Arsenical Compounds and Tartar Emetic by Normal and Resistant Trypanosomes and Its Relation to Drugresistance. J Pharmacol Exp Ther 59: 123-156.
10. Frommel TO, Balber AE, (1987) Flow cytofluorimetric analysis of drug accumulation by multidrug-resistant Trypanosoma brucei brucei and T. b. rhodesiense. Mol Biochem Parasitol 26: 183-191.
11. Mäser P, Lüscher A, Kaminsky R, (2003) Drug transport and drug resistance in African trypanosomes. Drug Resist Updat Rev Comment Antimicrob Anticancer Chemother 6: 281-290.
12. Vincent IM, Creek D, Watson DG, Kamleh MA, Woods DJ, et al. (2010) A molecular mechanism for eflornithine resistance in African trypanosomes. PLoS Pathog 6: e1001204 doi:10.1371/journal.ppat.1001204.
13. Baker N, Alsford S, Horn D, (2011) Genome-wide RNAi screens in African trypanosomes identify the nifurtimox activator NTR and the eflornithine transporter AAT6. Mol Biochem Parasitol 176: 55-57 doi:10.1016/j.molbiopara.2010.11.010.
14. Schumann Burkard G, Jutzi P, Roditi I, (2011) Genome-wide RNAi screens in bloodstream form trypanosomes identify drug transporters. Mol Biochem Parasitol 175: 91-94 doi:10.1016/j.molbiopara.2010.09.002.
15. ROLLO IM, WILLIAMSON J, (1951) Acquired resistance to "Melarsen", tryparsamide and amidines in pathogenic trypanosomes after treatment with "Melarsen" alone. Nature 167: 147-148.
16. De Koning HP, (2008) Ever-increasing complexities of diamidine and arsenical crossresistance in African trypanosomes. Trends Parasitol 24: 345-349 doi:10.1016/j.pt.2008.04.006.
17. Carter NS, Fairlamb AH, (1993) Arsenical-resistant trypanosomes lack an unusual adenosine transporter. Nature 361: 173-176 doi:10.1038/361173a0.
18. Carter NS, Berger BJ, Fairlamb AH, (1995) Uptake of diamidine drugs by the P2 nucleoside transporter in melarsen-sensitive and-resistant Trypanosoma brucei brucei. J Biol Chem 270: 28153-28157.
19. Mäser P, Sütterlin C, Kralli A, Kaminsky R, (1999) A nucleoside transporter from Trypanosoma brucei involved in drug resistance. Science 285: 242-244.
20. Matovu E, Stewart ML, Geiser F, Brun R, Mäser P, et al. (2003) Mechanisms of arsenical and diamidine uptake and resistance in Trypanosoma brucei. Eukaryot Cell 2: 1003-1008.
21. Bridges DJ, Gould MK, Nerima B, Mäser P, Burchmore RJS, et al. (2007) Loss of the high-affinity pentamidine transporter is responsible for high levels of cross-resistance between arsenical and diamidine drugs in African trypanosomes. Mol Pharmacol 71: 1098-1108 doi:10.1124/mol.106.031351.
22. De Koning HP, (2001) Uptake of pentamidine in Trypanosoma brucei brucei is mediated by three distinct transporters: implications for cross-resistance with arsenicals. Mol Pharmacol 59: 586-592.
23. Alsford S, Eckert S, Baker N, Glover L, Sanchez-Flores A, et al. (2012) High-throughput decoding of antitrypanosomal drug efficacy and resistance. Nature 482: 232-236 doi:10.1038/nature10771.
24. Baker N, Glover L, Munday JC, Aguinaga Andrés D, Barrett MP, et al. (2012) Aquaglyceroporin 2 controls susceptibility to melarsoprol and pentamidine in African trypanosomes. Proc Natl Acad Sci U S A 109: 10996-11001 doi:10.1073/pnas.1202885109.
25. Uzcategui NL, Szallies A, Pavlovic-Djuranovic S, Palmada M, Figarella K, et al. (2004) Cloning, heterologous expression, and characterization of three aquaglyceroporins from Trypanosoma brucei. J Biol Chem 279: 42669-42676 doi:10.1074/jbc.M404518200.
26. Bassarak B, Uzcátegui NL, Schönfeld C, Duszenko M, (2011) Functional characterization of three aquaglyceroporins from Trypanosoma brucei in osmoregulation and glycerol transport. Cell Physiol Biochem Int J Exp Cell Physiol Biochem Pharmacol 27: 411-420 doi:10.1159/000327968.
27. Liu Z, Shen J, Carbrey JM, Mukhopadhyay R, Agre P, et al. (2002) Arsenite transport by mammalian aquaglyceroporins AQP7 and AQP9. Proc Natl Acad Sci U S A 99: 6053-6058 doi:10.1073/pnas.092131899.
28. Gourbal B, Sonuc N, Bhattacharjee H, Legare D, Sundar S, et al. (2004) Drug uptake and modulation of drug resistance in Leishmania by an aquaglyceroporin. J Biol Chem 279: 31010-31017 doi:10.1074/jbc.M403959200.
29. Jackson AP, Sanders M, Berry A, McQuillan J, Aslett MA, et al. (2010) The genome sequence of Trypanosoma brucei gambiense, causative agent of chronic human african trypanosomiasis. PLoS Negl Trop Dis 4: e658 doi:10.1371/journal.pntd.0000658.
30. Berriman M, Ghedin E, Hertz-Fowler C, Blandin G, Renauld H, et al. (2005) The genome of the African trypanosome Trypanosoma brucei. Science 309: 416-422 doi:10.1126/science.1112642.
31. Baker N, de Koning HP, Mäser P, Horn D, (2013) Drug resistance in African trypanosomiasis: the melarsoprol and pentamidine story. Trends Parasitol 29: 110-118 doi:10.1016/j.pt.2012.12.005.
32. Stewart ML, Burchmore RJS, Clucas C, Hertz-Fowler C, Brooks K, et al. (2010) Multiple genetic mechanisms lead to loss of functional TbAT1 expression in drug-resistant trypanosomes. Eukaryot Cell 9: 336-343 doi:10.1128/EC.00200-09.
33. Matovu E, Geiser F, Schneider V, Mäser P, Enyaru JC, et al. (2001) Genetic variants of the TbAT1 adenosine transporter from African trypanosomes in relapse infections following melarsoprol therapy. Mol Biochem Parasitol 117: 73-81.
34. Nerima B, Matovu E, Lubega GW, Enyaru JCK, (2007) Detection of mutant P2 adenosine transporter (TbAT1) gene in Trypanosoma brucei gambiense isolates from northwest Uganda using allele-specific polymerase chain reaction. Trop Med Int Heal TM IH 12: 1361-1368 doi:10.1111/j.1365-3156.2007.01918.x.
35. Maina N, Maina KJ, Mäser P, Brun R, (2007) Genotypic and phenotypic characterization of Trypanosoma brucei gambiense isolates from Ibba, South Sudan, an area of high melarsoprol treatment failure rate. Acta Trop 104: 84-90 doi:10.1016/j.actatropica.2007.07.007.
36. Kazibwe AJN, Nerima B, de Koning HP, Mäser P, Barrett MP, et al. (2009) Genotypic status of the TbAT1/P2 adenosine transporter of Trypanosoma brucei gambiense isolates from Northwestern Uganda following melarsoprol withdrawal. PLoS Negl Trop Dis 3: e523 doi:10.1371/journal.pntd.0000523.
37. Pyana PP, Ngay Lukusa I, Mumba Ngoyi D, Van Reet N, Kaiser M, et al. (2011) Isolation of Trypanosoma brucei gambiense from cured and relapsed sleeping sickness patients and adaptation to laboratory mice. PLoS Negl Trop Dis 5: e1025 doi:10.1371/journal.pntd.0001025.
38. Baltz T, Baltz D, Giroud C, Crockett J, (1985) Cultivation in a semi-defined medium of animal infective forms of Trypanosoma brucei, T. equiperdum, T. evansi, T. rhodesiense and T. gambiense. EMBO J 4: 1273-1277.
39. Hirumi H, Hirumi K, (1989) Continuous cultivation of Trypanosoma brucei blood stream forms in a medium containing a low concentration of serum protein without feeder cell layers. J Parasitol 75: 985-989.
40. Räz B, Iten M, Grether-Bühler Y, Kaminsky R, Brun R, (1997) The Alamar Blue assay to determine drug sensitivity of African trypanosomes (T.b. rhodesiense and T.b. gambiense) in vitro. Acta Trop 68: 139-147.
41. Kaminsky R, Chuma F, Zweygarth E, (1989) Trypanosoma brucei brucei: expression of drug resistance in vitro. Exp Parasitol 69: 281-289.
42. Zweygarth E, Röttcher D, (1989) Efficacy of experimental trypanocidal compounds against a multiple drug-resistant Trypanosoma brucei brucei stock in mice. Parasitol Res 75: 178-182.
43. Gupta AB, Verma RK, Agarwal V, Vajpai M, Bansal V, et al. (2012) MIPModDB: a central resource for the superfamily of major intrinsic proteins. Nucleic Acids Res 40: D362-369 doi:10.1093/nar/gkr914.
44. De Koning HP, Anderson LF, Stewart M, Burchmore RJS, Wallace LJM, et al. (2004) The trypanocide diminazene aceturate is accumulated predominantly through the TbAT1 purine transporter: additional insights on diamidine resistance in african trypanosomes. Antimicrob Agents Chemother 48: 1515-1519.
45. Teka IA, Kazibwe AJN, El-Sabbagh N, Al-Salabi MI, Ward CP, et al. (2011) The diamidine diminazene aceturate is a substrate for the high-affinity pentamidine transporter: implications for the development of high resistance levels in trypanosomes. Mol Pharmacol 80: 110-116 doi:10.1124/mol.111.071555.
46. Munday JC, Rojas López KE, Eze AA, Delespaux V, Van Den Abbeele J, et al. (2013) Functional expression of TcoAT1 reveals it to be a P1-type nucleoside transporter with no capacity for diminazene uptake. Int J Parasitol Drugs Drug Resist 3: 69-76 doi:10.1016/j.ijpddr.2013.01.004.
47. Burri C, Stich A, Brun R (2004) Chemotherapy of Human African Trypanosomiasis. In: Maudlin I, Holmes PH, Miles MA, editors. The Trypanosomiasis. Wallingford, UK; Cambridge, MA, USA: CABI Pub. pp. 403-419.
48. Burri C, Baltz T, Giroud C, Doua F, Welker HA, et al. (1993) Pharmacokinetic properties of the trypanocidal drug melarsoprol. Chemotherapy 39: 225-234.
49. Felgner P, Brinkmann U, Zillmann U, Mehlitz D, Abu-Ishira S, (1981) Epidemiological studies on the animal reservoir of gambiense sleeping sickness. Part II. Parasitological and immunodiagnostic examination of the human population. Tropenmed Parasitol 32: 134-140.
50. Likeufack ACL, Brun R, Fomena A, Truc P, (2006) Comparison of the in vitro drug sensitivity of Trypanosoma brucei gambiense strains from West and Central Africa isolated in the periods 1960-1995 and 1999-2004. Acta Trop 100: 11-16 doi:10.1016/j.actatropica.2006.09.003.
51. Richner D, Brun R, Jenni L, (1988) Production of metacyclic forms by cyclical transmission of west African Trypanosoma (T.) brucei isolates from man and animals. Acta Trop 45: 309-319.
52. Brun R, Schumacher R, Schmid C, Kunz C, Burri C, (2001) The phenomenon of treatment failures in Human African Trypanosomiasis. Trop Med Int Heal TM IH 6: 906-914.
53. Maina NWN, Oberle M, Otieno C, Kunz C, Maeser P, et al. (2007) Isolation and propagation of Trypanosoma brucei gambiense from sleeping sickness patients in south Sudan. Trans R Soc Trop Med Hyg 101: 540-546 doi:10.1016/j.trstmh.2006.11.008.
54. Matovu E, Iten M, Enyaru JC, Schmid C, Lubega GW, et al. (1997) Susceptibility of Ugandan Trypanosoma brucei rhodesiense isolated from man and animal reservoirs to diminazene, isometamidium and melarsoprol. Trop Med Int Heal TM IH 2: 13-18.
55. Kaminsky R, Zweygarth E, (1989) Effect of in vitro cultivation on the stability of resistance of Trypanosoma brucei brucei to diminazene, isometamidium, quinapyramine, and Mel B. J Parasitol 75: 42-45.